Inbiomotion unravelling the enigma of breast cancer

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona and founder of Inbiomotion.

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona and founder of Inbiomotion.


The economics newspaper Expansión Catalunya has echoed the forthcoming publication of the results of a clinical assay of the MAF-Test, a diagnostic test for breast cancer patients developed by Inbiomotion, a spin-off from IRB Barcelona set up in 2010 by the researcher Roger Gomis. The results are expected to be out in November. This test may have the capacity to identify those breast cancer patients who would benefit from treatment with bisphosphonates, a class of drugs used to treat non-metastatic breast cancer, but whose administration can in many cases be counterproductive. If the results are positive, it is hoped that this test will reduce mortality from the disease by 31%.